Pfizer to Ask US Regulators to Authorize COVID Vaccine Booster for 5–11 Age Group

A child receives a dose of Pfizer's COVID-19 vaccine in Los Angeles, Calif., on Nov. 5, 2021. Frederic J. Brown/AFP via Getty Images

Pfizer and BioNTech plan on asking the U.S. Food and Drug Administration (FDA) to grant emergency use authorization for a booster for their COVID-19 vaccine for children aged 5- to 11-years-old, the companies announced on April 14.

The submission will be based on data from a Phase 2/3 clinical trial that showed a boost in antibodies from a booster dose, according to the companies.